Bayer Ag · XETR:BAYN
Bayer — The Angiogenesis 2025 Virtual Edition
22 slides from Bayer's conference presentation, Feb 8, 2025
Slide 1: Three-Year Outcomes of Aflibercept 8 mg in nAMD: PULSAR Extension Study
eu Sa Extension Three-Year Outcomes of Aflibercept 8 mg in nAMD: Safety and Efficacy Results From the PULSAR Extension Study Tien Y. Wong,'? on behalf of the PULSAR study investigators ‘Singapore Eye Re *Tsingt Presented at The Angiogenesis 2025 Virtual Edition, February 8, 2025
Slide 2: Disclosures
Disclosures ulsa nAMD Tien Y. Wong: Consulting fees from Aldropika Therapeutics, Bayer, Boehringer Ingelheim, Extension Eden Ophthalmic, Genentech, Iveric Bio/Astellas Pharma, Novartis, Oxurion, Plano, Roche, Sanofi, Shanghai Henlius, and Zhaoke Pharmaceutical; holds patents and is the co-founder of
Slide 3: PULSAR Extension Design
PULSAR Extension Design ulsa PULSAR nam (Masked) 2q8 arm Aflibercept 2 mg every 8 weeks after 3 initial monthly injections n=336 Patients with 8q12 arm treatment- Aflibercept 8 mg every 12 weeks naive after 3 initial monthly injections nAMD 8q16 arm Aflibercept 8 mg e after 3 initial monthly Primary
Slide 4: PULSAR Weeks 48 and 96: Key Results
PULSAR Weeks 48 and 96: Key Results Articles I Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial @r® At Weeks 48 and 96, patients receiving aflibercept 8 mg achieved comparable visu
Slide 5: PULSAR Extension Design
PULSAR Extension Design ulsa PULSAR PULSAR Extension eal (Masked) (Open-label & optional)? 2q8 arm Aflibercept 2 mg every 8 weeks after 3 initial monthly injections 2mg>8mg arm Patients originally assigned to 2q8 switched to aflibercept 8 mg every 12 weeks Patients n=208 with 8q12 arm treatment- erc
Slide 6: PULSAR Extension Design
PULSAR Extension Design ulsak nAMD Extension 2mg>8mg Patients initially treated with aflibercept 2q8 were switched to aflibercept 8 mg n=208 at Week 96 and immediately assigned to a 12-week dosing interval 8mg Patients initially treated with aflibercept 8q12 or 8q16 continued with aflibercept 8 mg n
Slide 7: Patient Disposition & Baseline Characteristics
Patient Disposition & Baseline Characteristics Patients entering PULSAR study (FAS), n PULSAR 2mg>8mg PULSAR Extension ig tal Patients entering PULSAR Extension (eFAS), n (%) 208 (61.9) 417 (62.0) 625 (61.9) Completion rate at Week 96, % Completion rate at Week 156, % 89.9> 90.4° 90.2 Age (years) 74
Slide 8: Mean BCVA Through Week 156
Mean BCVA? Through Week 156 ulsa nAMD Extension PULSAR (2q8 vs 8mg>) PULSAR Extension (2mg>8mg vs 8mg>) co Mean BCVA (ETDRS letters) 72 84 108 120 132 144 156 Week Mean number of injections va Mean number of injections from baseline to Week 96¢ from Week 96 to Week 156° 2q8: 12.8 2mg>8mg: 4.7 8q12/8
Slide 9: Mean CRT Through Week 156
Mean CRT? Through Week 156 PULSAR (2q8 vs 8mg>) € = = a () c o cy =
Slide 10: Mean CRT Through Week 156
Mean CRT? Through Week 156 ulsa nAMD PULSAR PULSAR Extension Extension (2q8 vs 8mg>) b fs) f=) Mean CRT (um) w fs) f=) 264 72 84 96 100 Week
Slide 11: Mean CRT Through Week 156
Mean CRT? Through Week 156 ulsa nAMD PULSAR PULSAR Extension Extension (2q8 vs 8mg>) b fs) f=) Mean CRT (um) w fs) f=) 72 84 96 104 Week
Slide 12: Mean CRT Through Week 156
b fs) f=) Mean CRT (um) w So o Mean CRT? Through Week 156 ulsa PULSAR (2q8 vs 8mg>) nAMD PULSAR Extension Extension Week 156 275 . —- ~~———» 108 120 132 144 «(156
Slide 13: Mean CRT Through Week 156
Mean CRT? Through Week 156 ulsa nAMD PULSAR PULSAR Extension Extension (2q8 vs 8mg>) (2mg>8mg vs 8mg°) Mean CRT (ym) b i=} oOo 120 132 144 LS mean CRT change (95% Cl) from baseline® =125 (-137, -113) =145 (-152, -137) 135 (-145, -125) -147 (-154, -141) 145 (-155, -136) =148 (-156, -140) *eFAS (obser
Slide 14: Majority of Aflibercept 8 mg-Treated Patients Completed Extended Dosing Intervals at Week 156
Majority of Aflibercept 8 mg-Treated Patients Completed Extended Dosing Intervals at Week 156 Last Completed Dosing Interval 35% fan 2Q20 23% @ Q24 i Q20-Q22 © Q16-Q18 @ Q12-Q14 B® Q8-Q10 Proportion of patients (%) 2mg>8mg? (n=186) eSAF, patients completing Week 156. Values may not add up to 100% du
Slide 15: Majority of Aflibercept 8 mg-Treated Patients Completed Extended Dosing Intervals at Week 156
Majority of Aflibercept 8 mg-Treated Patients Completed Extended Dosing Intervals at Week 156 ulsa Extension Last Completed Dosing Interval 21% @ Q24 M Q20-Q22 @ Q16-Q18 @ Q12-Q14 @ Q8-Q10 19% Proportion of patients (%) 8mg 2mg>8mg? (n=375)* (n=186) eSAF, patients completing Week 156. Values may not
Slide 16: Majority of Aflibercept 8 mg-Treated Patients Assigned Extended Dosing Intervals at Week 156
Majority of Aflibercept 8 mg-Treated Patients Assigned Extended Dosing Intervals at Week 156 Last Assigned Dosing Interval 9, 38% 24% 2Q20 18% @ Q24 i Q20-Q22 © Q16-Q18 @ Q12-Q14 B® Q8-Q10 Proportion of patients (%) 8q12 2mg>8mg? (n=185) (n=186) eSAF, patients completing Week 158. Values may not add
Slide 17: Majority of Aflibercept 8 mg-Treated Patients Assigned Extended Dosing Intervals at Week 156
Majority of Aflibercept 8 mg-Treated Patients ulsa Assigned Extended Dosing Intervals at Week 156 nAMD Extension Last Assigned Dosing Interval 24% @ Q24 M Q20-Q22 @ Q16-Q18 @ Q12-Q14 @ Q8-Q10 16% Proportion of patients (%) 8mg 2mg>8mg? (n=375)* (n=186) eSAF, patients completing Week 156. Values may
Slide 18: Ocular Safety From Main Baseline Through Week 156
Ocular Safety From Main Baseline l Through Week 1562 oer nAMD Extension 2mg>8&mg 208 N (eSAF) 417 625 Ocular TEAEs, n (%) 130 (62.5) 251 (60.2) 381 (61.0) Ocular SAEs, n (%) 7(3.4) 21 (5.0) 28 (4.5) Intraocular inflammation, n (%) 8 (1.9) 13 (2.1) Eye inflammation 1 (0.2) Iridocyclitis 4 (0.6) lriti
Slide 19: Non-Ocular Safety From Main Baseline Through Week 156
Non-Ocular Safety From Main Baseline l Through Week 1562 eee nAMD Extension N (eSAF) 625 Non-ocular SAEs, n (%) p d 149 (23.8) APTC events, n (%) p 5 1 (1.8) Deaths, n (%) 3 (2.1) *Cumulative events in the study eye from the main PULSAR study baseline through Week 156. APTC, Anti-Platelet Trialists'
Slide 20: PULSAR Extension: Key Week 156 Results
PULSAR Extension: Key Week 156 Results Functional and anatomic improvements observed in the PULSAR trial were largely maintained through Week 156 in the PULSAR Extension Mean BCVA and CRT were comparable at Week 156 between the 2mg>8mg and 8mg groups — These improvements were achieved with fewer inj
Slide 21: Aflibercept 8 mg Evidence Generation: 2025 and beyond
Aflibercept 8 mg Evidence Generation: 2025 and beyond Evidence generation studies Interventional Studies PULSAR - nAMD @-xot0nic PHOTON - DME Qiulsar Pa QUASAR - RVO Aieuteron ELARA - nAMD/DME * PHOTONIC - DME (China) é (Quasar * DEUTERON - nAMD/DME Fight Retinal Coy Blindness! Sea Sgn + SPECTRUM +
Slide 22: SPECTRUM: Global real-world study of aflibercept 8 mg
spectaum ) SPECTRUM: Global real-world study of aflibercept 8 mg A country and global cohort study in patients with treatment-naive or previously treated nAMD and DME across 18 countries Primary endpoint: Change in BCVA from baseline to Month 12 9 First patient in Feb 15, 2024 i+] | 7 | | a . x. | a